| __timestamp | Genmab A/S | Vertex Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 79529000 | 305409000 |
| Thursday, January 1, 2015 | 91224000 | 377080000 |
| Friday, January 1, 2016 | 102413000 | 432829000 |
| Sunday, January 1, 2017 | 146987000 | 496079000 |
| Monday, January 1, 2018 | 213695000 | 557616000 |
| Tuesday, January 1, 2019 | 342000000 | 658498000 |
| Wednesday, January 1, 2020 | 661000000 | 770456000 |
| Friday, January 1, 2021 | 1283000000 | 840100000 |
| Saturday, January 1, 2022 | 2676000000 | 944700000 |
| Sunday, January 1, 2023 | 3297000000 | 1136600000 |
| Monday, January 1, 2024 | 3790000000 | 1464300000 |
Unleashing insights
In the competitive landscape of biotechnology, understanding financial trends is crucial. Over the past decade, Vertex Pharmaceuticals and Genmab A/S have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Genmab A/S experienced a staggering increase in SG&A expenses, growing by over 4,000%, from approximately $80 million to $3.3 billion. This reflects Genmab's aggressive expansion and investment in administrative capabilities. In contrast, Vertex Pharmaceuticals saw a more modest increase of around 270%, from $305 million to $1.1 billion, indicating a steady yet controlled growth strategy. These trends highlight the differing strategic priorities of these biotech giants, with Genmab focusing on rapid scaling and Vertex maintaining a balanced approach. As the biotech industry continues to evolve, these financial insights provide a window into the strategic decisions shaping the future of healthcare.
Selling, General, and Administrative Costs: Pfizer Inc. vs Vertex Pharmaceuticals Incorporated
Breaking Down SG&A Expenses: Vertex Pharmaceuticals Incorporated vs Zoetis Inc.
Vertex Pharmaceuticals Incorporated and Teva Pharmaceutical Industries Limited: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Vertex Pharmaceuticals Incorporated or Exelixis, Inc.
Operational Costs Compared: SG&A Analysis of Vertex Pharmaceuticals Incorporated and Opthea Limited
Cost Management Insights: SG&A Expenses for Vertex Pharmaceuticals Incorporated and Ultragenyx Pharmaceutical Inc.
Vertex Pharmaceuticals Incorporated and Amneal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Vertex Pharmaceuticals Incorporated vs Viridian Therapeutics, Inc.
Genmab A/S and Lantheus Holdings, Inc.: SG&A Spending Patterns Compared
Genmab A/S and Opthea Limited: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Genmab A/S and Wave Life Sciences Ltd.
Breaking Down SG&A Expenses: Genmab A/S vs BioCryst Pharmaceuticals, Inc.